Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

"Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals


News provided by

BioRadar Ltd.

11 Nov, 2011, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, November 11, 2011 /PRNewswire/ --

- Replikins TransFlu™ Vaccine Now Available for Order from BioRadar UK Ltd.

Animals and humans no longer need to be "sitting ducks," oblivious to and unprepared for emergent infectious disease outbreaks. Rather than being caught off-guard by mass influenza outbreaks, UK-based biotech firm BioRadar Ltd. can successfully analyze the concentration and structure of the genomic Replikins in 'scout' viruses isolated from initial cases up to one year or longer, which provides advance warning of, and the ability to respond to the coming specific outbreaks (1,2).

(Photo:  http://photos.prnewswire.com/prnh/20111110/NY04916 )

More significantly, the advance warning affords BioRadar the time to produce specific solid-phase synthetic Replikins vaccines in seven days, and to test them thoroughly. Bulk production also takes days rather than months. Storage does not require refrigeration. For an example of current advance warning in H5N1 influenza, see Figure.

Specifically, BioRadar UK Ltd will make available the following synthetic updated Bogoch Replikins vaccines for animals: ReplikinsTransFlu™ against H5N1-H9N2-H1N1 Influenza Viruses in Poultry; ReplikinsFMD™ against Foot and Mouth Disease Virus in Livestock; ReplikinsTaura™ against Taura Syndrome Virus in Shrimp; and ReplikinsAMD™ against Aleutian Mink Disease Virus in mink.

The standard deviation of the mean (SD) indicates the population distribution of viruses with different Replikin Counts. At relatively low virus replication rates, the SD is small; the SD of the Replikin Counts increases with virus rapid replication, and an increase in the Mean follows (2).

BioRadar UK Ltd. has identified the specific Replikins in the H5N1 virus genome, both conserved and novel, which are currently building in concentration, increasing the risk of large outbreaks of H5N1 (Figure; Ref 3). The current H5N1 buildup, beginning in 2007 in birds, earlier in humans, resembles the Replikins buildup which led to the prediction in 2008 of the 2009 H1N1 Pandemic, one year in advance (1,2). Initial H5N1 and H1N1 cases are now occurring (7,8) and have led to the formulation of Synthetic Replikins Updated TransFlu™ Vaccines.

When the Replikins change again, the vaccine can be changed in 7 days.  The 'Two Punch' (against more than one gene) Replikins TransFlu™ vaccine has been proven effective against H5N1 in chickens and totally blocked virus excretion, making control of virus reservoirs possible (4).

In the previous H5N1 outbreaks between 1997 and 2011, the predictions published one year in advance, based on increases in Replikin Count™, have been followed invariably by strain-specific virus outbreaks (5-8).  In the Foot and Mouth Disease (FMD) virus genome, BioRadar identified both conserved (back to 1964) and new Replikins.  In 2009, FMD genomic Replikins increased in concentration to their highest level in 52 years and thus predicted, one year in advance (6), the current 2010-2011 outbreaks of FMD.  

Conclusions:

1. The new technology of the Replikins chemistry of the genome of pathogens makes accurate predictions of strain-specific outbreaks possible for the first time.

2. For each pathogen, the specific genomic Replikins are the basis for the specific Replikins Synthetic Vaccines.

3. When the genomic Replikins change, the vaccine can be changed in 7 days, providing ReplikinsUpdatedVaccines™.

The UN Food and Agriculture Organization (UN FAO) has noted the accuracy of Replikin Count™ predictions (8), and the UK Department of Trade and Investment has green-lighted BioRadar UK Ltd. (9).

   
    To receive product update information, e-mail to
    Vaccines@Replikins.com

    Name                         Company or Institution
    ______________________       ______________________

    Address                      Country
    ______________________       ______________________

    e-mail                       Telephone number
    ______________________       ______________________

    For price quotes, specify animal vaccine and indicate number of units
    required
                                     Number of units:
                                     ----------------
                                     (One unit = 100,000 doses of vaccine)
    ReplikinsPanFlu(TM) Vaccine      (__)
    Replikins FMD(TM) Vaccine        (__)
    AquaReplikinsTaura(TM) Vaccine   (__)
    ReplikinsAMD(TM) Vaccine         (__)
   
    References:
    1.       Replikins Press. Report No. 18. H1N1 Influenza Virus with
             Highest Replikin Count(TM) Since the 1918 Pandemic Identified in
             the U.S. and Austria (April 7, 2008) < replikins.com >
    2.       Bogoch, Samuel and Bogoch, Elenore. Prediction of specific virus
             outbreaks made from the increased concentration of a new class
             of virus genomic peptides, replikins. Available from Nature
             Precedings < http://dx.doi.org/10.1038/npre.2011.6279.1 >
             (2011)"
    3.       Bogoch, Samuel and Bogoch, Elenore. Marked Rise in Replikin
             Counts in H5N1 Influenza Virus Localized to p B1.Available from
             Nature Precedings< http://dx.doi.org/10.1038/npre.2011.6420.1 >
             (2011)
    4.       Jackwood MW, Bogoch, S., Bogoch ES, Hilt, D and Williams SW.
             Efficacy of a Replikin peptide Vaccine Against Low
             Pathogenicity Avian Influenza H5 Virus. Avian Diseases
             53(4):613-617, 2009.
    5.       Replikins Press Reports, Nos. 1-43, 2006-2011<replikins.com>
    6.       Replikins Press Reports, No. 37. Current Severe Outbreaks of
             Foot and Mouth Disease Predicted by Replikins' BioRadar(TM) One
             Year in Advance (June 2009) < replikins.com >
    7.       Replikins Press Reports, No. 36. Both H5N1 Bird Flu and H1N1
             Swine Flu Replikin Counts(TM) Increasing. April 9,
             2010<replikins.com>
    8.       Replikins Press Reports, No. 43. DVM Newsmagazine, UN Food and
             Agriculture Organization (FAO) discussion of Replikins.
             September 8, 2011< replikins.com >
    9.       Replikins Press Reports, No. 35. UK Trade and Investment
             article. BioRadar to set up HQ in Britain.  March 25,
             2010< replikins.com >

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.